Reported Earnings • Apr 23
First quarter 2026 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.30 (up from CN¥0.28 in 1Q 2025). Revenue: CN¥214.9m (up 1.4% from 1Q 2025). Net income: CN¥47.2m (up 6.1% from 1Q 2025). Profit margin: 22% (up from 21% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. Announcement • Apr 23
Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 14, 2026 Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 14, 2026, at 10:00 China Standard Time. Location: Building 3, Yard No. 7, Kexueyuan Road, Zhongguancun Life Science Park, Changping District, Beijing China Announcement • Mar 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 New Risk • Jan 06
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 165% Cash payout ratio: 153% Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.6% net profit margin). Announcement • Dec 26
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Nov 03
Third quarter 2025 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.23 (up from CN¥0.22 in 3Q 2024). Revenue: CN¥231.4m (down 4.1% from 3Q 2024). Net income: CN¥36.8m (up 9.1% from 3Q 2024). Profit margin: 16% (up from 14% in 3Q 2024). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • Sep 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Sep 02
Second quarter 2025 earnings released: EPS: CN¥0.30 (vs CN¥0.23 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.30 (up from CN¥0.23 in 2Q 2024). Revenue: CN¥248.9m (up 21% from 2Q 2024). Net income: CN¥46.5m (up 24% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. New Risk • Jul 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 210% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.4% net profit margin). Announcement • Jun 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • May 10
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Dividend per share is over 22x earnings per share. The company is paying a dividend despite having no free cash flows. Dividend yield: 20% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 22x earnings per share. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.4% net profit margin). Reported Earnings • Apr 28
First quarter 2025 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.28 (up from CN¥0.27 in 1Q 2024). Revenue: CN¥212.0m (up 6.4% from 1Q 2024). Net income: CN¥44.5m (up 6.8% from 1Q 2024). Profit margin: 21% (in line with 1Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. New Risk • Apr 27
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Dividend is not well covered by cash flows (98% cash payout ratio). Announcement • Apr 26
Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025 Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025, at 10:00 China Standard Time. Location: Building 3, Yard No. 7, Kexueyuan Road, Zhongguancun Life Park, Changping District, Beijing China Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥27.21, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.2% over the past three years. Announcement • Mar 28
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Dec 27
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.36 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.22 (down from CN¥0.36 in 3Q 2023). Revenue: CN¥241.3m (down 10% from 3Q 2023). Net income: CN¥33.8m (down 39% from 3Q 2023). Profit margin: 14% (down from 21% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 9% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥24.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥46.03 per share. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.43 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.43 in 2Q 2023). Revenue: CN¥205.8m (down 28% from 2Q 2023). Net income: CN¥37.5m (down 44% from 2Q 2023). Profit margin: 18% (down from 24% in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Announcement • Jun 28
Beijing Konruns Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.16 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.27 (up from CN¥0.16 in 1Q 2023). Revenue: CN¥199.2m (up 21% from 1Q 2023). Net income: CN¥41.7m (up 62% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 7% per year. Announcement • Apr 27
Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024 Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024, at 11:00 China Standard Time. Location: The Company's Meeting Room, Beijing China Reported Earnings • Apr 09
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.96 (up from CN¥0.65 in FY 2022). Revenue: CN¥920.0m (up 6.1% from FY 2022). Net income: CN¥150.5m (up 48% from FY 2022). Profit margin: 16% (up from 12% in FY 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 5.3%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Mar 29
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥25.03, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 15x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past three years. Announcement • Dec 29
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Announcement • Sep 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q3, 2023 results on Oct 28, 2023 Reported Earnings • Aug 01
Second quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.22 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.43 (up from CN¥0.22 in 2Q 2022). Revenue: CN¥285.7m (up 33% from 2Q 2022). Net income: CN¥67.2m (up 89% from 2Q 2022). Profit margin: 24% (up from 17% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Beijing Konruns Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 01, 2023 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report first half, 2023 results on Aug 01, 2023 Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥32.79, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total loss to shareholders of 5.3% over the past three years. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.16 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥165.1m (up 5.7% from 1Q 2022). Net income: CN¥25.7m (down 45% from 1Q 2022). Profit margin: 16% (down from 30% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Buying Opportunity • Dec 14
Now 21% undervalued Over the last 90 days, the stock is up 10.0%. The fair value is estimated to be CN¥34.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.1% over the last 3 years. Earnings per share has declined by 28%. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Zhongyi Su was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥28.74, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past three years. Reported Earnings • Oct 26
Third quarter 2022 earnings released Third quarter 2022 results: Net income: (down CN¥37.2m from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥30.36, the stock trades at a trailing P/E ratio of 36.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total loss to shareholders of 16% over the past three years. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.30 (down from CN¥0.41 in 1Q 2021). Revenue: CN¥156.2m (down 26% from 1Q 2021). Net income: CN¥46.4m (down 28% from 1Q 2021). Profit margin: 30% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Director Xiaobo Lu is the most experienced director on the board, commencing their role in 2020. Independent Director Zhongyi Su was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.25 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: CN¥141.0m (down 30% from 3Q 2020). Net income: CN¥37.2m (down 3.9% from 3Q 2020). Profit margin: 26% (up from 19% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.44 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥244.5m (down 12% from 2Q 2020). Net income: CN¥35.6m (down 50% from 2Q 2020). Profit margin: 15% (down from 26% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.20 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥211.1m (up 198% from 1Q 2020). Net income: CN¥64.4m (up 100% from 1Q 2020). Profit margin: 31% (down from 45% in 1Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Mar 23
Full year 2020 earnings released: EPS CN¥1.15 (vs CN¥1.66 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥808.6m (down 24% from FY 2019). Net income: CN¥183.4m (down 31% from FY 2019). Profit margin: 23% (down from 25% in FY 2019). The decrease in margin was driven by lower revenue. Announcement • Jan 22
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 23, 2021 Is New 90 Day High Low • Jan 14
New 90-day low: CN¥34.99 The company is down 14% from its price of CN¥40.65 on 16 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥36.29 The company is down 9.0% from its price of CN¥39.80 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Nov 12
New 90-day low: CN¥37.02 The company is down 23% from its price of CN¥48.05 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥38.43 The company is down 29% from its price of CN¥53.82 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Reported Earnings • Oct 20
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥204.1m, down 34% from the prior year. Total revenue was CN¥854.7m over the last 12 months, down 18% from the prior year. Announcement • Oct 19
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 20, 2020 Beijing Konruns Pharmaceutical Co.,Ltd. announced that they will report Q3, 2020 results on Oct 20, 2020 Announcement • Jul 17
Beijing Konruns Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 1.0563854 billion in funding from CBC Group and another investor Beijing Konruns Pharmaceutical Co.,Ltd. (SHSE:603590) announced a private placement of 32,919,457 A shares for the gross proceeds of CNY 1,056,385,400 on July 13, 2020. The transaction will include participation from CBC IV Investment Eight Limited , a fund managed by CBC Group for 21,813,649 shares at a gross proceeds of CNY 700,000,000 and Wang Xijuan for 11,105,808 shares for the gross proceeds of CNY 356,385,400. The transaction has been approved by the seventh meeting of the third board of supervisors of the company.